Enveric Biosciences Announces Reverse Stock Split
Enveric Biosciences (NASDAQ: ENVB) announced a 1-for-50 reverse stock split effective July 14, 2022. This adjustment will reduce the outstanding shares from approximately 52.7 million to 1.05 million. Shareholders will not need to exchange certificates, as adjustments will be made automatically for shares held in brokerage accounts. This split is aimed at improving the company's stock price and maintaining its listing on the Nasdaq Capital Market. The company focuses on developing psychedelic-inspired mental health medicines.
- Reduction of outstanding shares from 52,684,548 to approximately 1,053,691 shares may enhance the stock price.
- The reverse split is designed to maintain compliance with Nasdaq listing requirements.
- Potential fractional share dilution for stockholders.
- The effectiveness of the reverse stock split on stock price is uncertain.
Common Stock Will Begin Trading on a Split-Adjusted Basis on
At a special meeting of stockholders held on
At the effective time of the reverse stock split, every 50 shares of Enveric’s issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-50 reverse stock split. It is not necessary for stockholders holding shares of the Company’s common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the reverse stock split will be rounded up to the nearest whole number of shares. The reverse stock split will reduce the number of shares of Enveric’s common stock outstanding from 52,684,548 shares to approximately 1,053,691 shares. Proportional adjustments will be made to the number of shares of Enveric’s common stock issuable upon exercise or conversion of Enveric’s equity awards and warrants, as well as the applicable exercise price. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record may direct questions to the Company’s transfer agent,
About
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the effect that the reverse stock split may have on the price of our common stock; our ability to retain our listing on the Nasdaq Capital Market; the ability of the company to successfully spin-off its cannabinoid assets; the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005172/en/
Investor Contacts
212.896.1254
valter@kcsa.com
Media Contacts
212.896.1267
asoss@kcsa.com
Source:
FAQ
What is the reverse stock split ratio for Enveric Biosciences?
When will the reverse stock split for ENVB take effect?
How will the reverse stock split affect my shares of ENVB?
What is the reason behind Enveric's reverse stock split?
How many shares will be outstanding after the reverse stock split for ENVB?
